PT  - JOURNAL ARTICLE
AU  - Sangha, Veer
AU  - Dhingra, Lovedeep Singh
AU  - Oikonomou, Evangelos
AU  - Aminorroaya, Arya
AU  - Sikand, Nikhil V
AU  - Sen, Sounok
AU  - Krumholz, Harlan M
AU  - Khera, Rohan
TI  - Identification of Hypertrophic Cardiomyopathy on Electrocardiographic Images with Deep Learning
AID  - 10.1101/2023.12.23.23300490
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.23.23300490
4099  - http://medrxiv.org/content/early/2023/12/28/2023.12.23.23300490.short
4100  - http://medrxiv.org/content/early/2023/12/28/2023.12.23.23300490.full
AB  - Background Hypertrophic cardiomyopathy (HCM) affects 1 in every 200 individuals and is the leading cause of sudden cardiac death in young adults. HCM can be identified using an electrocardiogram (ECG) raw voltage data and deep learning approaches, but their point-of-care application is limited by the inaccessibility of these signal data. We developed a deep learning-based approach that overcomes this limitation and detects HCM from images of 12-lead ECGs across layouts.Methods We identified ECGs from patients with HCM features present on cardiac magnetic resonance imaging (CMR) or those within 30 days of an echocardiogram documenting thickened interventricular septum (end-diastolic interventricular septum thickness > 15mm). Patients with CMR-confirmed HCM were considered as cases during the final model evaluation. The model was validated within clinical settings at YNHH and externally on ECG images from the prospective, population-based UK Biobank cohort. We localized class-discriminating signals in ECG images using gradient-weighted class activation mapping.Results Overall, 124,553 ECGs from 66,987 individuals (HCM cases and controls) were used for model development. The model demonstrated high discrimination for HCM across various ECG image formats and calibrations in internal validation (area under receiving operation characteristics [AUROC] 0.96) and external sets of ECG images from UK Biobank (AUROC 0.94). A positive screen for HCM was associated with a 100-fold higher odds of CMR-confirmed HCM (OR 102.4, 95% Confidence Interval, 57.4 – 182.6) in the held-out set. Class-discriminative patterns localized to the anterior and lateral leads (V4-V5).Conclusions We developed and externally validated a deep learning model that identifies HCM from ECG images with excellent discrimination. This approach represents an automated, efficient, and accessible screening strategy for HCM.Competing Interest StatementMr. Sangha and Dr. Khera are the coinventors of U.S. Provisional Patent Application No. 63/346,610, 'Articles and methods for format-independent detection of hidden cardiovascular disease from printed electrocardiographic images using deep learning' and are co-founders of Ensight-AI. Dr. Khera receives support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775) and the Doris Duke Charitable Foundation (under award 2022060). He receives support from the Blavatnik Foundation through the Blavatnik fund for Innovation at Yale. He also receives research support, through Yale, from Bristol-Myers Squibb, and Novo Nordisk. He is an Associate Editor at JAMA. In addition to 63/346,610, Dr. Khera is a coinventor of U.S. Provisional Patent Applications 63/177,117, 63/428,569, and 63/484,426. Dr. Khera and Dr. Oikonomou are co-founders of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. Dr. Oikonomou is a co-inventor of the U.S. Patent Applications 63/508,315 & 63/177,117 and has served as a consultant to Caristo Diagnostics Ltd (all outside the current work).Funding StatementThe study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775 to Dr. Khera) and the Doris Duke Charitable Foundation (under award, 2022060 to Dr. Khera).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Yale Institutional Review Board approved the study protocol and waived the need for informed consent as the study represents a secondary analysis of existing data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes